Peer Review History
| Original SubmissionDecember 22, 2020 |
|---|
|
Pécs, Hungary February 2, 2021 PONE-D-20-40185 Whole brain and deep gray matter structure segmentation: quantitative comparison between MPRAGE and MP2RAGE sequences PLOS ONE Dear Dr. Droby, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised by the Reviewers, listed below. Please submit your revised manuscript by Mar 20 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Joseph Najbauer, Ph.D. Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Thank you for stating the following in the Competing Interest section: "NG: serves as a member of the Editorial Board for the Journal of Parkinson's Disease. He serves as consultant to Sionara, Accelmed, Teva, NeuroDerm, Intec Pharma, Pharma2B, Denali and Abbvie. He receives royalties from Lysosomal Therapeutics (LTI) and payment for lectures at Teva, UCB, Abbvie, Sanofi-Genzyme, Bial and Movement Disorder Society. He received research support from the Michael J Fox Foundation, the National Parkinson Foundation, the European Union 7th Framework Program and the Israel Science Foundation as well as from Teva NNE program, Biogen, LTI, and Pfizer. RMH is an employee of and owns stock in Biogen. JC: is a former employee of Biogen. " We note that one or more of the authors have an affiliation to the commercial funders of this research study : Biogen Inc. 2.1. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form. Please also include the following statement within your amended Funding Statement. “The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.” If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement. 2.2. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc. Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests). If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf. Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests 3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. In your revised cover letter, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. We will update your Data Availability statement on your behalf to reflect the information you provide. 4. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: I Don't Know ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The authors investigated the agreement of brain tissues (white matter, grey matter and deep grey matter) volumes obtained from MP2RAGE compared to MPRAGE. The authors compared the volumes obtained from different segmentation methods at baseline and 1 year follow-up to assess the accuracy and the reproducibility of volumetric measures. The authors showed the relevance of using MP2RAGE to estimate brain volumes. I have few comments and questions to the authors: Material and Methods -Please provide more detailed description of the used segmentation methods. -Please provide demographical information for the longitudinal group. -Please explain why you did not used a removing background noise method on the MP2RAGE and N3/N4 bias field correction on the MPRAGE before tissues classification (O’Brian et al., 2014) ? Results -Please provide the CNR difference between DGM and WM. -Please provide a Figure for each tissue segmentation estimated by the used methods. -Please provide the results of the intra-modality voxel-wise differences between baseline and follow-up as well as the inter-modality voxel-wise differences at follow-up. -What about inter and intra-modality cortical thickness differences at baseline and follow-up? -Table 4: please provide mean percentage change overtime for WM volume. Discussion -Please discuss the potential effect of background noise on tissues classification. -Please update your discussion according to my comments/questions. Reviewer #2: In this work, Droby et al. compared whole brain, cortical and subcortical gray, and white matter tissue segmentations between results based on MP2RAGE and MPRAGE data and different segmentation software, as well as between data acquired at different time points (1 yr apart). Across a total of 29 subjects, they found that MP2RAGE data is characterized by significant higher CNR leading to differences in subcortical and white and gray matter tissue probabilities, depending on the segmentation tool used. Comparative studies such as this are important to validate popular sequences, in this case MPRAGE and MP2RAGE, for anatomical imaging. Especially clinical researchers that rely on accurate segmentation of brain structures will benefit from this work and/or enable them to better design acquisition and analysis protocols. Therefore, I see the value of this manuscript but think it must take care of the following major issues to consider publication: First, with regards to the impact of data quality and CNR analysis: 1. The authors define the sequence-specific CNR as the difference between the mean values of GM and WM, divided by the sum of squares of their standard deviation. However, ideally, CNR values need to be corrected for differences in total acquisition time (T) as longer acquisition (such as for the MP2RAGE sequence) positively affect achievable CNR. As such, current CNR needs to be converted to CNR per unit time, by normalizing it to the square root of T (in minutes) as for example done in https://doi.org/10.3389/fnana.2016.00112. This, as well as the fact that the MP2RAGE T1w image is a combination of two separate inversion images, and thus based on more data, needs to be further discussed to put the results in perspective. 2. Considering that the quality of the data might vary across the brain due to B1 transmit and receive homogeneity differences, as mentioned in the introduction by the authors too, I think it would be of interest to see whether difference in CNR between MPRAGE and MP2RAGE varies across the brain, and whether this spatial variation is more prominent for MPRAGE or MP2RAGE. This could be tested by averaging per lobe for example and will also ease interpretation of the observed differences between tissue probability maps. 3. In line my previous comment and with the authors’ hypothesis stated in the discussion that the observed differences in CNR “can be explained by the differences between the two sequences, and the fact that increased rates of bias-field effects are inherent in MP-RAGE images at high and ultra-high magnetic fields (≥3 Tesla), whereas, MP2RAGE is less sensitive to B1 bias, thus enabling the acquisition of images with enhanced” I would propose to calculate subject-specific difference maps between the MP-RAGE and MP2RAGE images (e.g., after normalization to the average CSF value, for example). This will provide a surrogate bias map and might provide additional information with regards to origin of the observed differences in terms of tissue segmentation. See also https://doi.org/10.3389/fnana.2016.00112 and https://doi.org/10.1016/j.neuroimage.2020.117373 for relevant demonstrations and discussions on the effect of B1 biases on cortical and subcortical segmentations using MP2RAGE data. With regards to the tissue probability map comparisons: 4. Import details are lacking with regards to the voxel-based analyses of the tissue probability maps. The authors should elaborate more on the SPM analyses as it is impossible now for the reader to replicate the current analyses. For example, which registration tool was used? And why was chosen for a linear registration instead of non-linear transformation? The latter will ensure larger overlap across subjects for statistical analyses and more power. Moreover, did the authors coregister each MP-RAGE and MP2RAGE image individually to the template space or did they use the same transformation matrix for both types of images? This coregistration process should be clarified to rule out potential sources of biases in the comparison. 5. Finally, it is confusing why the WM results using volBrain are not shown in Figure 2 as for CAT-12 and FSL-FAST and as suggested in the caption. In general: 6. Especially in the introduction the authors should better emphasize the novelty of the current work (e.g., compared to https://doi.org/10.1002/jmri.24960). 7. I think the paper would benefit from an extra table/figure that summarizes all findings. This will make it easier for the reader to identify the key message of the manuscript and follow the narrative of the discussion. Minor points Introduction: 8. Define ‘high’ and ‘ultra-high’ magnetic field strengths 9. Last paragraph, ‘doesn’t’ to ‘does not’ Test-retest reliability (methods): 10. Add characteristics for the test-retest subjects 11. First sentence: ‘described above’ to ‘described below’ or move paragraph 12. Second sentence: a. Change ‘T1-MPRAGE’ to MP-RAGE to follow previous notations b. Change ‘patients’ to ‘participants’ MRI acquisition protocol (methods): 13. No need to define MP-RAGE again. 14. Remove sequence parameters from text as this is redundant with Table 1. Also add readout bandwidth to better estimate SNR and interpret the CNR differences. 15. Last sentence: would be informative for the reader to add a bit more detail what the authors are referring to with ‘Table 1 & Figure 1’ MRI data processing (methods): 16. As for MP-RAGE, no need to define CNR again. Whole brain tissue segmentation (methods): 17. First sentence: change ‘free-widely’ to ‘free and widely’ 18. Last sentence: c. ‘Montreal neurological institute’ to ‘Montreal Neurological Institute’ Contrast-to-noise (methods): 19. Subscript ‘WG’ in ‘CNRWG’ as used in the equation and later in the results DGM segmentation (methods): 20. I do not understand why there is a difference in the tools used for whole-brain and DGM segmentation. I would suggest using the same set of tools across both analyses or motivate why it was chosen not to. Statistical analysis (methods)s: 21. Is there are specific reason why the authors did not use a multivariate (i.e., across multiple regions of interest) ANOVA test for the statistical differences? This will also allow to test for the effect of segmentation tools, region of interest and/or potential interactions. Whole-brain volumes (results): 22. I think it would be helpful for the reader to see example tissue segmentation results for a single subject using both types of data. This could for example be combined with Figure 1. DGM segmentation (results): 23. Second sentence: ‘accumbnes’ to ‘accumbens’ Test-retest reliability (results): 24. First sentence: d. ‘MP2RGAE’ to ‘MP2RAGE’ e. Higher what? Volume? Please specify ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Pécs, Hungary May 13, 2021 PONE-D-20-40185R1 Whole brain and deep gray matter structure segmentation: quantitative comparison between MPRAGE and MP2RAGE sequences PLOS ONE Dear Dr. Droby, Thank you for submitting your manuscript (R1 version) to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised by Reviewer #2. Please submit your revised manuscript by Jun 27 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Joseph Najbauer, Ph.D. Academic Editor PLOS ONE Journal Requirements: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: No ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: No ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: I would like to thank the authors for addressing all my comments. I have no additional comments regarding the revised manuscript. Reviewer #2: I appreciate the authors' efforts to accommodate most of my concerns, which has improved the manuscript. I like the new Figure 3, which nicely shows the differences for the GM, WM and CSF segmentations between acquisitions for each method. WM and CSF are generally larger based on MPRAGE data using FSL-FAST (especially) and volBrain, while more similar using CAT12. The opposite is true for GM. In addition, I thank the authors for calculating CNR per lobe and I think this is informative and should be added to the main text. Finally, I recommend further clarification of a couple of remaining issues: - The authors state that 'MP2RAGE resulted in more accurate brain tissue segmentation' (abstract). This needs to be rephrased as the 'ground truth' is not known so it is difficult to define 'more accurate', or, it should be clarified what they mean with 'more accurate'. - I think the difference between the MPRAGE and MP2RAGE sequences need to be emphasized more. Especially in terms of how the T1w-like image is obtained (i.e., synthesized) for the MP2RAGE sequence. - In their response to my comment #3, the authors provided a intra-subject difference map based on the segmentation results. Although informative as well, what I was suggesting was to calculate the difference between the raw images. This allows characterization of any spatial bias in the difference between MPRAGE and MP2RAGE data. For example, are differences larger towards the frontal lobe? - Please verify that CNR values were calculated using the raw T1w images, and elaborate on what the potential impact of readout bandwidth differences between MPRAGE and MP2RAGE acquisitions on CNR could be. - I would advise to add the T-statistical value and degrees of freedom to the statistical results. Also, specify that the non-binary probability masks were used and if statistical testing was restricted to GM and/or WM (i.e., masked), or not. Figures: - Figure 1, if possible, I would recommend to use data from the same subject for all sub-panels. - Figure 4, it is very difficult to see the significant voxels. I would advise to zoom in on the interesting part and only show that in the figure. Some minor textual comments I noticed: - Abstract: 'In a sub-study, twelve participants were scanned after one year.' change to ' rescanned' - Abstract: 'Mean ± SD = 0.97 ± 0.04 and 0.8 ± 0.1 respectively; p<0.0001' change 'and' to 'vs' - Introduction, last paragraph: 'different widely available, open-source automatic segmentation tools' remove open-source. I was not able to find the source code for volBrain - Methods, CNRwg: 'corrected per scan time' change to 'normalized for scan time' - Please go through the manuscript to correct small grammatical errors. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: Yes: Roy Haast [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
Pécs, Hungary June 29, 2021 Whole brain and deep gray matter structure segmentation: quantitative comparison between MPRAGE and MP2RAGE sequences PONE-D-20-40185R2 Dear Dr. Droby, We’re pleased to inform you that your manuscript (R2 version) has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. PLEASE NOTE: References 1, and 10 are not complete (the last names of the authors are missing, also the year of publication and the journal volume and page naumbers are missing - PLEASE CORRECT. PLEASE CHECK ALL REFERENECES FOR COMPLETENESS AND ACCURACY. PLEASE CHECK THE ENTIRE MANUSCRIPT FOR COMPLETENESS AND ACCURACY. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Joseph Najbauer, Ph.D. Academic Editor PLOS ONE ------------------------------------ Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #2: No ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #2: (No Response) ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #2: Yes: Roy AM Haast |
| Formally Accepted |
|
PONE-D-20-40185R2 Whole brain and deep gray matter structure segmentation: quantitative comparison between MPRAGE and MP2RAGE sequences Dear Dr. Droby: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Joseph Najbauer Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .